Literature DB >> 17719727

Safety, tolerability and subject-rated effects of acute intranasal cocaine administration during atomoxetine maintenance.

William W Stoops1, John W Blackburn, David A Hudson, Lon R Hays, Craig R Rush.   

Abstract

The results of recent research indicate that agonist replacement may be a viable option in the treatment of cocaine dependence. For example, d-amphetamine and modafinil have shown promise in managing cocaine dependence in preliminary clinical trials. The aim of this study was to determine the physiological and subject-rated effects of acute intranasal cocaine doses during chronic atomoxetine treatment. Atomoxetine was chosen because it produces pharmacological and subject-rated effects similar to those of prototypical stimulants and thus may also be a viable agonist replacement therapy. To this end, seven cocaine-dependent subjects were maintained on doses of atomoxetine (0mg [lead in], 5, 10, 20 and 0mg [washout], four times daily) for 3-5 days prior to completing experimental sessions in which ascending doses of intranasal cocaine (4, 20, 40 and 60 mg) were administered. Cocaine produced prototypical cardiovascular and subject-rated effects. Atomoxetine attenuated the systolic pressure increasing effects and enhanced the heart rate increasing effects of cocaine, but was otherwise devoid of effects. These results indicate that cocaine is well tolerated during atomoxetine maintenance. Further research is needed to better determine the effects of atomoxetine and cocaine combinations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17719727      PMCID: PMC2213369          DOI: 10.1016/j.drugalcdep.2007.07.005

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  22 in total

1.  Dissociation between subjective and behavioral responses after cocaine stimuli presentations.

Authors:  S A Dudish-Poulsen; D K Hatsukami
Journal:  Drug Alcohol Depend       Date:  1997-07-25       Impact factor: 4.492

Review 2.  The pharmacology of cocaine related to its abuse.

Authors:  C E Johanson; M W Fischman
Journal:  Pharmacol Rev       Date:  1989-03       Impact factor: 25.468

3.  Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans.

Authors:  Joshua A Lile; William W Stoops; Todd M Durell; Paul E A Glaser; Craig R Rush
Journal:  Exp Clin Psychopharmacol       Date:  2006-05       Impact factor: 3.157

4.  Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys.

Authors:  M S Kleven; E W Anthony; W L Woolverton
Journal:  J Pharmacol Exp Ther       Date:  1990-07       Impact factor: 4.030

5.  The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.

Authors:  O Lingjaerde; U G Ahlfors; P Bech; S J Dencker; K Elgen
Journal:  Acta Psychiatr Scand Suppl       Date:  1987

6.  Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects.

Authors:  N A Farid; R F Bergstrom; E A Ziege; C J Parli; L Lemberger
Journal:  J Clin Pharmacol       Date:  1985 May-Jun       Impact factor: 3.126

7.  Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys.

Authors:  Maciej Gasior; Jack Bergman; Mary Jeanne Kallman; Carol A Paronis
Journal:  Neuropsychopharmacology       Date:  2005-04       Impact factor: 7.853

8.  Caffeine drug discrimination in humans: acquisition, specificity and correlation with self-reports.

Authors:  A H Oliveto; W K Bickel; J R Hughes; P J Shea; S T Higgins; J W Fenwick
Journal:  J Pharmacol Exp Ther       Date:  1992-06       Impact factor: 4.030

9.  Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine.

Authors:  Sunmee Wee; William L Woolverton
Journal:  Drug Alcohol Depend       Date:  2004-09-06       Impact factor: 4.492

10.  Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials.

Authors:  John Grabowski; Howard Rhoades; Angela Stotts; Katherine Cowan; Charles Kopecky; Anne Dougherty; F Gerard Moeller; Sohela Hassan; Joy Schmitz
Journal:  Neuropsychopharmacology       Date:  2004-05       Impact factor: 7.853

View more
  19 in total

1.  Atomoxetine in abstinent cocaine users: Cognitive, subjective and cardiovascular effects.

Authors:  Elise E DeVito; Aryeh I Herman; Noah S Konkus; Huiping Zhang; Mehmet Sofuoglu
Journal:  Pharmacol Biochem Behav       Date:  2017-07-14       Impact factor: 3.533

2.  Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy.

Authors:  Craig R Rush; William W Stoops; Lon R Hays
Journal:  Drug Alcohol Depend       Date:  2008-10-15       Impact factor: 4.492

Review 3.  Novel medications to treat addictive disorders.

Authors:  Iván D Montoya; Frank Vocci
Journal:  Curr Psychiatry Rep       Date:  2008-10       Impact factor: 5.285

4.  Physiological and subjective effects of acute intranasal methamphetamine during atomoxetine maintenance.

Authors:  Craig R Rush; William W Stoops; Joshua A Lile; Paul E A Glaser; Lon R Hays
Journal:  Pharmacol Biochem Behav       Date:  2011-07-23       Impact factor: 3.533

5.  College students' use of cocaine: results from a longitudinal study.

Authors:  Sarah J Kasperski; Kathryn B Vincent; Kimberly M Caldeira; Laura M Garnier-Dykstra; Kevin E O'Grady; Amelia M Arria
Journal:  Addict Behav       Date:  2010-12-10       Impact factor: 3.913

Review 6.  Prefrontal cortex and drug abuse vulnerability: translation to prevention and treatment interventions.

Authors:  Jennifer L Perry; Jane E Joseph; Yang Jiang; Rick S Zimmerman; Thomas H Kelly; Mahesh Darna; Peter Huettl; Linda P Dwoskin; Michael T Bardo
Journal:  Brain Res Rev       Date:  2010-09-15

7.  Atomoxetine attenuates dextroamphetamine effects in humans.

Authors:  Mehmet Sofuoglu; James Poling; Kevin Hill; Thomas Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

Review 8.  Norepinephrine and stimulant addiction.

Authors:  Mehmet Sofuoglu; R Andrew Sewell
Journal:  Addict Biol       Date:  2008-09-22       Impact factor: 4.280

Review 9.  Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.

Authors:  José Pérez de los Cobos; Núria Siñol; Víctor Pérez; Joan Trujols
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

10.  Safety of atomoxetine in combination with intravenous cocaine in cocaine-experienced participants.

Authors:  Louis Cantilena; Roberta Kahn; Connie C Duncan; Shou-Hua Li; Ann Anderson; Ahmed Elkashef
Journal:  J Addict Med       Date:  2012-12       Impact factor: 3.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.